No mortality benefit with high-flow nasal oxygen in immunocompromised patients with acute hypoxemic respiratory failure

No mortality benefit with high-flow nasal oxygen in immunocompromised patients with acute hypoxemic respiratory failure is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central